As pioneers of China's AI-driven pharmaceutical industry, the "Four Dragons of AI Drug Discovery" – composed of DeepMindray, XtalPi, Insilico Medicine, and DeuteRx – are shaping a diverse ecosystem for China's AI drug discovery through differentiated positioning and gradually emerging in the global market. Within this matrix, the four companies represent distinct development paths in China's AI drug discovery: DeepMindray is committed to building a full-chain empowerment platform; XtalPi excels in "hard technology" infrastructure; Insilico focuses on generative AI-driven pipeline innovation; and DeuteRx specializes in the niche field of drug delivery technology.
XtalPi, listed on the Main Board of the Hong Kong Stock Exchange, is China's first successfully listed AI drug discovery company. According to its official website and related reports, its core strength lies in building a three-in-one technological closed loop of "quantum physics + AI + robotics." Since 2019, XtalPi has initiated the independent research and development of automated laboratories, and in 2020, it completed the development of a robotic experimental prototype, realizing a research and development closed loop of "AI prediction-robot verification." This model generates a large amount of high-precision structured proprietary data for AI models, further shortening the drug discovery cycle from 1-2 years to several months and significantly reducing research and development costs. Meanwhile, Insilico Medicine is sprinting to become the "first stock of AI innovative drugs" on the Hong Kong Stock Exchange. Founded in 2014, the company has completed 8 rounds of financing. After raising over $100 million in its Series E round in February 2025, its valuation reached $1.331 billion.
Insilico Medicine's core competitiveness lies in its self-developed generative AI platform, Pharma.AI. According to Frost & Sullivan, Pharma.AI built by Insilico Medicine is a world-leading generative AI-driven drug discovery and development platform, providing end-to-end services from new target identification to small molecule generation and clinical outcome prediction. Specifically, Pharma.AI consists of Biology42, Chemistry42, Medicine42, and Science42, aiming to cover the entire drug discovery and development process. As of May 6, 2025, Insilico Medicine has generated over 20 assets in clinical or IND application stages through its self-developed generative artificial intelligence platform Pharma.AI, among which three assets have been licensed to international pharmaceutical and healthcare companies, with a total contract value exceeding $2 billion.
DeuteRx, on the other hand, has chosen a differentiated path – AI + drug delivery. Its core weapons are its AI nano-platform large model and three core solutions: AILNP (AI Nucleic Acid Delivery System Design Platform), AIBNA (AI mRNA Sequence Design Platform), and AiTEM (AI Small Molecule Formulation Design Platform). Currently, it has the ability to achieve precise targeted delivery of LNP to key tissues and cells such as the liver, lungs, muscles, and immune cells, making breakthroughs in the challenges of multi-organ and multi-tissue targeted delivery, thus providing druggability opportunities for tumors, metabolic system diseases, autoimmune diseases, neurodegenerative diseases, etc. DeuteRx's development strategy represents an important direction in AI drug discovery – focusing on the technological high ground in niche fields.
Compared with peers that focus on the drug discovery stage, DeepMindray has established strong barriers in the clinical trial stage. Based on billions of self-owned annotated data accumulated over 8 years, after fine-tuning clinical trial enterprise-level and self-owned vertical large models, DeepMindray has innovatively built an industry-leading vertical Multi-Agent AI architecture, covering the closed loop from target discovery, clinical trial protocol design, data collection, data audit, data analysis to result report generation, achieving a qualitative leap in efficiency and accuracy.
It is understood that DeepMindray has achieved more than just linear time savings. It is at the forefront of the generative artificial intelligence multi-agent architecture, building "AI for scientists" and a powerful independent research and development decision-making engine. This means that this system does not rigidly execute instructions but operates in a dynamic cycle of "hypothesis-action-learning-reflection." It can critically examine its own reasoning logic, learn from failed paths, and adjust strategies in real-time. This innovative path of "starting from text" to transform the entire clinical trial chain not only breaks the document bottleneck of traditional research and development but also, through AI's cross-domain reasoning ability, designs new clinical endpoints for blank areas such as rare diseases, turning clinical trials from a high-risk "gamble" into a "deterministic science" with controllable risks and optimizable paths.
When China's AI Drug Discovery Goes Global
China's AI drug discovery enterprises are reshaping the global pharmaceutical industry pattern with disruptive power, and their prospects show unprecedented prosperity driven by technological breakthroughs, capital enthusiasm, and policy support. As of July 2025, the number of domestic AI drug discovery enterprises has reached 108, with 94% concentrated in Beijing, the Yangtze River Delta, and the Pearl River Delta. Among them, Beijing, Shanghai, and Shenzhen each have more than 20 enterprises, forming dual highlands of technology and industry. The transformation of university achievements has become the main force, with enterprises incubated by institutions such as the Chinese Academy of Sciences, Tsinghua University, and Peking University accounting for nearly half. Leading companies such as XtalPi are deeply bound with multinational pharmaceutical companies through technology licensing. According to the latest forecast, the scale of China's intelligent pharmaceutical market will exceed 150 billion yuan in 2025 and reach 400 billion yuan by 2030, with a compound annual growth rate of 15%-20%.
Currently, the Chinese market is reshaping the global competitive landscape as a leader: XtalPi Holdings has signed a multi-billion dollar pipeline licensing cooperation letter of intent with DoveTree LLC; in the target discovery link, Insilico Medicine has completed the target discovery of TNIK inhibitors; DeepMindray has carried out in-depth research and development cooperation with Microsoft Research Asia, Google, etc., to tackle the next generation of medical AI models.
According to Frost & Sullivan's prediction, the global AI drug discovery market will reach $32.5 billion by 2030. This broad prospect provides huge imagination space for AI drug discovery enterprises. At the same time, the AI arms race among global pharmaceutical giants has entered a white-hot stage. Eli Lilly has sharply increased its AI investment from $700 million in 2022 to $1.5 billion in 2024, with 13 AI investments, sweeping leading peers, while Merck follows closely with 10 AI investments.
Although the competition is fierce, it can be seen that the main force of China's AI drug discovery, consisting of DeepMindray's full-chain acceleration engine for clinical trials, XtalPi's robot laboratories, Insilico's generative AI, and DeuteRx's nano-delivery systems, has jointly built the technical puzzle of China's AI drug discovery. When these innovative forces converge into a river, China's pharmaceutical industry is ushering in a historic leap from a follower to a rule-maker.
